Evolus Expands Global Footprint with Introduction of Treatment in Australia

The performance beauty company, Evolus, has begun operations in Australia with the launch of Nuceiva, a prabotulinumtoxinA.

Nuceiva is approved by the Therapeutic Goods Administration (TGA) for the temporary improvement in the appearance of moderate to severe glabella lines in adult patients. 

“Launching Evolus in Australia underscores our commitment to strategic geographic expansion and our dedicated focus on customers in this growth market,” said David Moatazedi, President and Chief Executive Officer. “This milestone fuels our global growth strategy by establishing a strong presence in a key region. Successfully entering new markets like Australia positions us for sustained above-market growth, reinforcing Evolus’ position as a global leader in its industry.” 

The company has established a direct operating entity in Australia, under the leadership of Daniel Henry. Working closely with aesthetics healthcare professionals will enable Evolus to offer this new treatment to patients. The product is licensed in the US under the brand name Jeuveau. 

It’s been the fastest-growing neurotoxin in the US for 3 consecutive years. 

Safety and efficacy of Nuceiva has been evaluated through the company’s transparency clinical program, three Phase III trials, including the largest head-to-head aesthetic pivotal study versus, Botox (onabotulinumtoxinA) to date, and two long-term safety studies. 

Side effects were similar to other products in this class of medicine. For the full list of adverse events, warnings and contraindications consult the Nuceiva Prescribing Information.

Renowned plastic surgeon and medical director Steve Liew, MD, at Shape Clinic in Sydney says beauty in Australia continues to evolve with the younger generations gaining curiosity about non-surgical enhancement and rejuvenation options.

“With their unapologetically millennial focus, I’m excited to be working with Evolus as they expand to Australia,” said Dr. Liew. “By offering aesthetics healthcare professionals more choice, practitioners like me will be able to deliver optimal outcomes tailored to each patient's evolving beauty preferences and needs.”